[REVISION HISTORY]

Advancements in AI-driven cancer blood tests

7 recorded revisions of this situation.

What changed

2026-10-21 17:41 UTC → 2026-10-23 23:51 UTC · added ~~removed~~

Advancements in liquid biopsy technology continue to evolve, with research emphasizing the ability to detect cancer years before clinical diagnosis. A longitudinal study involving the Ontario Health Study found that epigenetic alterations and cell-free DNA signatures can appear in blood plasma up to eight years before a ~~diagnosis. Recent research involving over 275,000 patients has further supported the utility of longitudinal blood analysis, suggesting that changes~~ diagnosis, with particularly strong molecular warning signs noted in ~~routine test results can signal~~ prostate cancer ~~risk three to five years before physical symptoms appear.~~ patients. In clinical applications, the Melody trial at Cork University Hospital is investigating liquid biopsies as a less invasive alternative to traditional tissue biopsies for identifying genetic characteristics in advanced breast cancers. Regarding pancreatic cancer, an international research team ~~led by the US-based City of Hope has~~ developed ~~a new~~ the PANXEON blood ~~test called PANXEON. Published in Nature Medicine, this liquid biopsy~~ test, which utilizes artificial intelligence to analyze ~~three specific markers:~~ circulating microRNA, exosomal microRNA, and the protein CA 19-9. In clinical ~~testing involving approximately 1,800 participants across the US, Europe, and Asia, the~~ testing, this method correctly identified 87% of pancreatic cancers at stages 1 and ~~2, while also identifying high-grade dysplasia~~ 2. Additionally, researchers at the Mayo Clinic have used AI to analyze CT scans, finding that changes in ~~over 64%~~ subcutaneous and visceral fat may serve as early indicators of ~~cases.~~ pancreatic cancer. Further developments in Multicancer Early Detection (MCED) are being highlighted by experts from the National and Kapodistrian University of ~~Athens and Alexandra Hospital.~~ Athens. This approach utilizes blood tests to simultaneously detect multiple cancer types by analyzing cell-free DNA for specific methylation patterns. The PATHFINDER 2 study has demonstrated that the Galleri test can significantly increase the detection of various cancers, including pancreatic, ovarian, and liver cancer, with a 91.3% accuracy in predicting the likely organ of origin. Clinical data from the NHS-Galleri study, a large-scale randomized trial in ~~England involving 142,250 participants,~~ England, supports the value of this method in identifying cancer signals and ~~predicting the organ of origin.~~ guiding subsequent diagnostic procedures.

Versions

Select a version to see what changed compared to the one before it.